MARKET INSIGHTS
Global (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide (CAS 1217486-61-7) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 31.2 million in 2026 to USD 67.8 million by 2034, exhibiting a CAGR of 9.0% during the forecast period.
(2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide (CAS 1217486-61-7) is a specialized pyrrolidine-based small molecule compound characterized by a thiazole core linked to a trifluoromethyl‑substituted pyridine moiety. The compound is recognized as a potent and selective inhibitor with relevance in oncology and targeted therapeutic research, particularly in kinase inhibition pathways. Its structurally complex architecture – incorporating chiral centers, fluorinated substituents, and heterocyclic scaffolds – renders it a highly valued reference compound and research chemical in pharmaceutical development and medicinal chemistry investigations.
The market is steadily gaining traction, driven by growing pharmaceutical R&D expenditure, increasing focus on precision oncology, and heightened demand for structurally defined research‑grade compounds in drug discovery pipelines. Furthermore, the rising adoption of targeted small‑molecule therapies and the expanding role of contract research organizations (CROs) in early‑phase drug development are reinforcing demand. Key suppliers serving this niche market include specialized fine chemical manufacturers and API development firms with capabilities in complex heterocyclic synthesis.
🔟 1. MedChemExpress
Headquarters: China
Key Offering: High‑purity intermediates for kinase inhibitor development
MedChemExpress specializes in providing high‑purity pyrrolidine‑based intermediates for pharmaceutical R&D. Their extensive synthetic expertise supports complex heterocyclic chemistry, enabling rapid development of novel oncology agents.
Sustainability/Growth Initiatives:
- Investment in green fluorination technologies to reduce waste
- Expansion of ISO‑certified GMP facilities
- Partnerships with leading biotech firms for custom synthesis
9️⃣ 2. Cayman Chemical
Headquarters: USA
Key Offering: Analytical reference standards and high‑purity research compounds
Cayman Chemical provides rigorously validated reference materials for academic and industrial research, ensuring reproducibility and compliance with regulatory standards.
Sustainability/Growth Initiatives:
- Adoption of renewable energy in manufacturing
- Development of low‑toxicity synthesis routes
- Expansion of digital chemistry platforms for rapid delivery
8️⃣ 3. Biosynth
Headquarters: Switzerland
Key Offering: GMP‑compliant API synthesis and custom intermediates
Biosynth delivers high‑quality API solutions with a focus on precision oncology, supporting both small‑molecule and biologic development pipelines.
Sustainability/Growth Initiatives:
- Implementation of closed‑loop solvent recovery systems
- Investment in biocatalytic fluorination processes
- Collaborations with academic institutions for green chemistry research
7️⃣ 4. Apollo Scientific
Headquarters: United Kingdom
Key Offering: Custom synthesis and scale‑up services for complex heterocycles
Apollo Scientific offers tailored synthetic routes for challenging pyrrolidine‑based compounds, enabling efficient scale‑up for preclinical and clinical studies.
Sustainability/Growth Initiatives:
- Adoption of energy‑efficient reaction vessels
- Development of biodegradable purification resins
- Partnerships with CROs to streamline early‑stage development
6️⃣ 5. TargetMol
Headquarters: USA
Key Offering: High‑purity small‑molecule intermediates for kinase inhibitors
TargetMol focuses on delivering chiral, high‑purity intermediates that meet stringent regulatory requirements for oncology therapeutics.
Sustainability/Growth Initiatives:
- Implementation of green solvent protocols
- Investment in scalable fluorination catalysts
- Collaboration with pharma partners for joint development programs
5️⃣ 6. Selleck Chemicals
Headquarters: USA
Key Offering: Broad portfolio of research compounds and custom synthesis
Selleck Chemicals offers a wide range of research chemicals and supports custom synthesis, facilitating rapid iteration in drug discovery projects.
Sustainability/Growth Initiatives:
- Use of renewable feedstocks in synthesis
- Optimization of reaction conditions to reduce waste
- Expansion of online ordering platform for global reach
4️⃣ 7. Chemsky
Headquarters: Shanghai, China
Key Offering: Custom synthesis of fluorinated heterocycles
Chemsky specializes in complex fluorinated heterocycle synthesis, providing tailored solutions for academic and industrial clients.
Sustainability/Growth Initiatives:
- Implementation of energy‑saving reactors
- Development of waste‑minimizing purification techniques
- Collaboration with regional universities for talent development
3️⃣ 8. DC Chemicals
Headquarters: China
Key Offering: High‑purity intermediates and API development
DC Chemicals offers a range of high‑purity compounds with a strong focus on API development for the pharmaceutical sector.
Sustainability/Growth Initiatives:
- Adoption of low‑energy synthesis routes
- Investment in recycling of fluorinated waste streams
- Expansion of global distribution network
2️⃣ 9. Finetech Industry Limited
Headquarters: China
Key Offering: Scalable synthesis of complex heterocycles
Finetech Industry focuses on scalable production of complex heterocyclic intermediates, supporting large‑volume API manufacturing.
Sustainability/Growth Initiatives:
- Development of catalytic fluorination systems
- Implementation of waste‑reduction protocols
- Collaboration with CROs for rapid scale‑up
1️⃣ 10. Hubei Jusheng Technology Co., Ltd.
Headquarters: China
Key Offering: Custom synthesis and chiral separation services
Hubei Jusheng provides custom synthesis and advanced chiral separation, ensuring high enantiomeric purity for pharmaceutical applications.
Sustainability/Growth Initiatives:
- Adoption of green chemistry principles in all processes
- Investment in high‑efficiency separation technologies
- Partnerships with global pharma for joint development
Download FREE Sample Report: (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide (CAS 1217486-61-7) Market – View in Detailed Research Report
🌍 Outlook: The Future of (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide (CAS 1217486-61-7) Market
The (2S)-N1‑compound market is poised for continued expansion driven by the global shift toward precision oncology and the integration of advanced small‑molecule therapeutics. The forecasted growth to USD 67.8 million by 2034 underscores the increasing investment in kinase inhibitor pipelines and the demand for high‑purity research intermediates.
📈 Key Trends Shaping the Market:
- Rapid adoption of PROTAC and ADC platforms leveraging the trifluoro‑pyridine scaffold.
- Expansion of contract research organizations in Asia‑Pacific driving large‑scale synthesis.
- Green chemistry innovations reducing fluorination waste and lowering production costs.
- Intensified focus on chiral purity and regulatory compliance to meet global standards.
- Strategic collaborations between fine‑chemical manufacturers and biotech firms to accelerate pipeline development.
- Top 10 Companies in the Polyurethane Flange Sealants Market (2026): Market Leaders Powering Global Sealing Solutions - June 8, 2026
- Top 10 Companies in the Global Fine Atomized Ferrosilicon Market (2026): Market Leaders Driving Industry Growth - June 8, 2026
- Top 10 Companies in the Polyester Polyol Intermediates Market (2026): Market Leaders Powering Global Growth - June 8, 2026